Takeda bolsters global business development through new US unit
This article was originally published in Scrip
Takeda has set up a new global business development group at its wholly owned Takeda Pharmaceuticals International subsidiary in the US, which will have broad responsibilities for product licensing and mergers and acquisitions.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.